EUVIMEDEUVIMED entdecken
Crossref

Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience

Emre Urhan

Anadolu Kliniği Tıp Bilimleri Dergisi · 23.05.2026 · 31 (2) · 302-309

DOI: 10.21673/anadoluklin.1840385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anadolu Kliniği Tıp Bilimleri Dergisi, online erschienen am 23.05.2026. Verfasst von Emre Urhan. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the early glycemic, weight, and metabolic effects of the fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) in patients with uncontrolled type 2 diabetes mellitus (T2DM) despite treatment with oral antidiabetic agents (OADs) and/or single or multiple insulin regimens, and to generate real-world evidence regarding its clinical effectiveness.

Methods

This retrospective single-center study included adults with T2DM who initiated iGlarLixi at Burdur State Hospital between June 2024 and January 2025 and used it for at least three months. Patients aged ≥ 18 years with body mass index (BMI) > 35 kg/m² and hemoglobin A1c (HbA1c) ≥ 7% were included. iGlarLixi was administered once daily (100/33 or 100/50) with dose titration to fasting glucose targets. Baseline and 3-month measurements of weight, BMI, HbA1c, fasting glucose, lipid profile, and routine laboratory parameters were compared.

Results

Among the 65 individuals enrolled, 62 were able to complete the 3-month course of iGlarLixi therapy. During follow-up, we noted reductions in body weight, BMI, HbA1c, fasting plasma glucose, and triglycerides, whereas high-density lipoprotein cholesterol showed a significant rise. Overall, 71% of patients showed a reduction in HbA1c and 29% achieved HbA1c

Zitieren

APA

Urhan, E. (2026). Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience. Anadolu Kliniği Tıp Bilimleri Dergisi, 31(2), 302-309. https://doi.org/10.21673/anadoluklin.1840385

Vancouver

Urhan E. Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience. Anadolu Kliniği Tıp Bilimleri Dergisi. 2026;31(2):302-309. doi:10.21673/anadoluklin.1840385

BibTeX
@article{Urhan2026,
  author = {Urhan, Emre},
  title = {Early glycemic, weight, and metabolic effects of insulin glargine/lixisenatide in uncontrolled type 2 diabetes: A single-center experience},
  journal = {Anadolu Kliniği Tıp Bilimleri Dergisi},
  year = {2026},
  volume = {31},
  number = {2},
  pages = {302--309},
  doi = {10.21673/anadoluklin.1840385}
}
Kostenlos starten →